OSE Stock Overview
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
OSE Immunotherapeutics SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €6.70 |
52 Week High | €8.63 |
52 Week Low | €2.71 |
Beta | 0.78 |
1 Month Change | -10.07% |
3 Month Change | 39.58% |
1 Year Change | 91.98% |
3 Year Change | -41.54% |
5 Year Change | 87.15% |
Change since IPO | -35.89% |
Recent News & Updates
Recent updates
Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?
May 23We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Oct 02We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Apr 30OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be
May 11Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?
May 08Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher
Mar 16How Is OSE Immunotherapeutics' (EPA:OSE) CEO Paid Relative To Peers?
Dec 01Shareholder Returns
OSE | FR Biotechs | FR Market | |
---|---|---|---|
7D | -14.6% | -7.4% | -4.2% |
1Y | 92.0% | -23.2% | 1.8% |
Return vs Industry: OSE exceeded the French Biotechs industry which returned -23.2% over the past year.
Return vs Market: OSE exceeded the French Market which returned 1.8% over the past year.
Price Volatility
OSE volatility | |
---|---|
OSE Average Weekly Movement | 9.3% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 4.5% |
10% most volatile stocks in FR Market | 9.3% |
10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: OSE's share price has been volatile over the past 3 months.
Volatility Over Time: OSE's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 55 | Nicolas Poirier | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
OSE fundamental statistics | |
---|---|
Market cap | €145.41m |
Earnings (TTM) | -€23.00m |
Revenue (TTM) | €2.23m |
65.3x
P/S Ratio-6.3x
P/E RatioIs OSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OSE income statement (TTM) | |
---|---|
Revenue | €2.23m |
Cost of Revenue | €0 |
Gross Profit | €2.23m |
Other Expenses | €25.23m |
Earnings | -€23.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.06 |
Gross Margin | 100.00% |
Net Profit Margin | -1,032.91% |
Debt/Equity Ratio | 182.4% |
How did OSE perform over the long term?
See historical performance and comparison